JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

Kodu・Aktsiate loetelu・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Suletud

1.14 4.59

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.1400000000000001

Max

1.15

Põhinäitajad
By Trading Economics
Sissetulek	17M -26M
Töötajad	171
EBITDA	19M -23M

Soovitused
By TipRanks
Soovitused	Müü
12 kuu keskmine prognoos	+266.97% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	26. veebr 2026

Turustatistika
By TradingEconomics
Turukapital	-29M 73M
Eelmine avamishind	-3.45
Eelmine sulgemishind	1.14

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

1.43 / 1.6 Toetus ja vastupanu

Pliant Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

7. veebr 2026, 09:20 UTC

Market Talk

Financial Services Roundup: Market Talk

7. veebr 2026, 09:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

7. veebr 2026, 05:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

7. veebr 2026, 02:46 UTC

Omandamised, ülevõtmised, äriostud

Big Money, High Anxiety -- Barrons.com

6. veebr 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

6. veebr 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

6. veebr 2026, 21:40 UTC

Omandamised, ülevõtmised, äriostud

Verizon Insiders Rarely Sell Company Stock. This Insider Just Did. -- Barrons.com

6. veebr 2026, 21:22 UTC

Market Talk

Mexico's Inflation Seen Accelerating in January -- Market Talk

6. veebr 2026, 21:17 UTC

Tulu

Toyota Smashes Earnings Estimates. It's Getting a New CEO. -- Barrons.com

6. veebr 2026, 21:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

6. veebr 2026, 21:14 UTC

Omandamised, ülevõtmised, äriostud

Justice Department Casts Wide Net on Netflix's Business Practices in Merger Probe -- Update

6. veebr 2026, 21:13 UTC

Tulu

How the Software Panic Hit BDC Stocks -- and Why Some Might Be Worth Buying -- Barrons.com

6. veebr 2026, 21:13 UTC

Tulu

Amazon, Strategy, Robinhood, Novo Nordisk, Molina, Stellantis, Hub Group, and More Stock Market Movers -- Barrons.com

6. veebr 2026, 21:04 UTC

Market Talk

Gold Closes Out Volatile Week on Higher Note -- Market Talk

6. veebr 2026, 20:34 UTC

Tulu

Tech Had an Awful Earnings Season. Other Stocks Are Saving the Day. -- Barrons.com

6. veebr 2026, 20:27 UTC

Tulu

These Stocks Are Today's Movers: Amazon, Strategy, Robinhood, Novo Nordisk, Molina, Stellantis, Hub Group, and More -- Barrons.com

6. veebr 2026, 20:24 UTC

Market Talk

Oil Futures Settle Higher As U.S.-Iran Talks Get Under Way -- Market Talk

6. veebr 2026, 20:20 UTC

Market Talk

U.S. Natural Gas Futures Retreat Ahead of Weekend -- Market Talk

6. veebr 2026, 19:48 UTC

Tulu

Take-Two, Mondelez Get Analyst Attention -- Barrons.com

6. veebr 2026, 19:30 UTC

Omandamised, ülevõtmised, äriostud

Justice Department Casts Wide Net on Netflix's Business Practices in Merger Probe -- WSJ

6. veebr 2026, 19:30 UTC

Omandamised, ülevõtmised, äriostud

Justice Department Asking Industry How Netflix or Paramount Deal for Warner Bros. Might Impact Competition, According to Subpoena -- WSJ

6. veebr 2026, 19:30 UTC

Omandamised, ülevõtmised, äriostud

DOJ Asking if Netflix Engaged in 'Exclusionary Conduct' That May Lead to Monopoly, According to Subpoena -- WSJ

6. veebr 2026, 19:17 UTC

Market Talk

USDA Says Farm Income to Decrease in 2026 -- Market Talk

6. veebr 2026, 18:50 UTC

Tulu

Toyota Smashes Earnings Estimates. It's Getting a New CEO. -- Barrons.com

6. veebr 2026, 18:47 UTC

Market Talk

Natural Gas-Infrastructure Operators Take 'Flight to Scale' -- Market Talk

6. veebr 2026, 18:34 UTC

Market Talk

U.S. Oil Rig Count Rises By 1 to 412 -- Market Talk

6. veebr 2026, 17:58 UTC

Tulu

Reddit Stock Falls After Strong Earnings. Wall Street Is Debating What's Next. -- Barrons.com

6. veebr 2026, 17:52 UTC

Market Talk

Tulu

Global Equities Roundup: Market Talk

6. veebr 2026, 17:52 UTC

Market Talk

Tulu

Amazon's CapEx Seen as Misunderstood by Investors -- Market Talk

6. veebr 2026, 17:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Pliant Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

266.97% tõus

12 kuu keskmine prognoos

Keskmine 4 USD 266.97%

Kõrge 4 USD

Madal 4 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Pliant Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Müü

3 ratings

Osta

Hoia

Müü

Põhineb 3 analüütiku instrumendi Pliant Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.43 / 1.6Toetus ja vastupanu

Recent bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.